Dawei Jiang1,2, Hyung-Jun Im2,3, Haiyan Sun2, Hector F Valdovinos4, Christopher G England4, Emily B Ehlerding4, Robert J Nickles4, Dong Soo Lee3, Steve Y Cho2, Peng Huang5, Weibo Cai6,7,8. 1. Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University, Shenzhen, 518060, China. 2. Department of Radiology, University of Wisconsin - Madison, Room 7137, 1111 Highland Ave, Madison, WI, 53705-2275, USA. 3. Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea. 4. Department of Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA. 5. Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University, Shenzhen, 518060, China. peng.huang@szu.edu.cn. 6. Department of Radiology, University of Wisconsin - Madison, Room 7137, 1111 Highland Ave, Madison, WI, 53705-2275, USA. wcai@uwhealth.org. 7. Department of Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA. wcai@uwhealth.org. 8. University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA. wcai@uwhealth.org.
Abstract
PURPOSE: Human epidermal growth factor receptor 2 (HER2) is over-expressed in over 30% of ovarian cancer cases, playing an essential role in tumorigenesis and metastasis. Non-invasive imaging of HER2 is of great interest for physicians as a mean to better detect and monitor the progression of ovarian cancer. In this study, HER2 was assessed as a biomarker for ovarian cancer imaging using 64Cu-labeled pertuzumab for immunoPET imaging. METHODS: HER2 expression and binding were examined in three ovarian cancer cell lines (SKOV3, OVCAR3, Caov3) using in vitro techniques, including western blot and saturation binding assays. PET imaging and biodistribution studies in subcutaneous models of ovarian cancer were performed for non-invasive in vivo evaluation of HER2 expression. Additionally, orthotopic models were employed to further validate the imaging capability of 64Cu-NOTA-pertuzumab. RESULTS: HER2 expression was highest in SKOV3 cells, while OVCAR3 and Caov3 displayed lower HER2 expression. 64Cu-NOTA-pertuzumab showed high specificity for HER2 (Ka = 3.1 ± 0.6 nM) in SKOV3. In subcutaneous tumors, PET imaging revealed tumor uptake of 41.8 ± 3.8, 10.5 ± 3.9, and 12.1 ± 2.3%ID/g at 48 h post-injection for SKOV3, OVCAR3, and Caov3, respectively (n = 3). In orthotopic models, PET imaging with 64Cu-NOTA-pertuzumab allowed for rapid and clear delineation of both primary and small peritoneal metastases in HER2-expressing ovarian cancer. CONCLUSIONS: 64Cu-NOTA-pertuzumab is an effective PET tracer for the non-invasive imaging of HER2 expression in vivo, rendering it a potential tracer for treatment monitoring and improved patient stratification.
PURPOSE:Human epidermal growth factor receptor 2 (HER2) is over-expressed in over 30% of ovarian cancer cases, playing an essential role in tumorigenesis and metastasis. Non-invasive imaging of HER2 is of great interest for physicians as a mean to better detect and monitor the progression of ovarian cancer. In this study, HER2 was assessed as a biomarker for ovarian cancer imaging using 64Cu-labeled pertuzumab for immunoPET imaging. METHODS:HER2 expression and binding were examined in three ovarian cancer cell lines (SKOV3, OVCAR3, Caov3) using in vitro techniques, including western blot and saturation binding assays. PET imaging and biodistribution studies in subcutaneous models of ovarian cancer were performed for non-invasive in vivo evaluation of HER2 expression. Additionally, orthotopic models were employed to further validate the imaging capability of 64Cu-NOTA-pertuzumab. RESULTS:HER2 expression was highest in SKOV3 cells, while OVCAR3 and Caov3 displayed lower HER2 expression. 64Cu-NOTA-pertuzumab showed high specificity for HER2 (Ka = 3.1 ± 0.6 nM) in SKOV3. In subcutaneous tumors, PET imaging revealed tumor uptake of 41.8 ± 3.8, 10.5 ± 3.9, and 12.1 ± 2.3%ID/g at 48 h post-injection for SKOV3, OVCAR3, and Caov3, respectively (n = 3). In orthotopic models, PET imaging with 64Cu-NOTA-pertuzumab allowed for rapid and clear delineation of both primary and small peritoneal metastases in HER2-expressing ovarian cancer. CONCLUSIONS:64Cu-NOTA-pertuzumab is an effective PET tracer for the non-invasive imaging of HER2 expression in vivo, rendering it a potential tracer for treatment monitoring and improved patient stratification.
Authors: Dana Faratian; Annelien J M Zweemer; Yoko Nagumo; Andrew H Sims; Morwenna Muir; Michael Dodds; Peter Mullen; Inhwa Um; Charlene Kay; Max Hasmann; David J Harrison; Simon P Langdon Journal: Clin Cancer Res Date: 2011-05-13 Impact factor: 12.531
Authors: C Jackisch; S-B Kim; V Semiglazov; B Melichar; X Pivot; C Hillenbach; D Stroyakovskiy; B L Lum; R Elliott; H A Weber; G Ismael Journal: Ann Oncol Date: 2014-11-17 Impact factor: 32.976
Authors: Werner Scheuer; Thomas Friess; Helmut Burtscher; Birgit Bossenmaier; Josef Endl; Max Hasmann Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701
Authors: Kristin McLarty; Bart Cornelissen; Zhongli Cai; Deborah A Scollard; Danny L Costantini; Susan J Done; Raymond M Reilly Journal: J Nucl Med Date: 2009-07-17 Impact factor: 10.057
Authors: Haiming Luo; Reinier Hernandez; Hao Hong; Stephen A Graves; Yunan Yang; Christopher G England; Charles P Theuer; Robert J Nickles; Weibo Cai Journal: Proc Natl Acad Sci U S A Date: 2015-09-28 Impact factor: 11.205
Authors: A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks Journal: Cancer Res Date: 1990-07-01 Impact factor: 12.701
Authors: J M Bartlett; S P Langdon; B J Simpson; M Stewart; D Katsaros; P Sismondi; S Love; W N Scott; A R Williams; A M Lessells; K G Macleod; J F Smyth; W R Miller Journal: Br J Cancer Date: 1996-02 Impact factor: 7.640
Authors: Shiyong Li; Christopher G England; Emily B Ehlerding; Christopher J Kutyreff; Jonathan W Engle; Dawei Jiang; Weibo Cai Journal: Am J Transl Res Date: 2019-09-15 Impact factor: 4.060
Authors: Hye Jin Lee; Emily B Ehlerding; Dawei Jiang; Todd E Barnhart; Tianye Cao; Weijun Wei; Carolina A Ferreira; Peng Huang; Jonathan W Engle; Weibo Cai Journal: Am J Cancer Res Date: 2019-07-01 Impact factor: 6.166